Published in Mol Ther on June 17, 2008
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Physical approaches to biomaterial design. Nat Mater (2009) 4.01
Endocytosis of nanomedicines. J Control Release (2010) 3.23
Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev (2012) 2.11
More effective nanomedicines through particle design. Small (2011) 1.80
Engineering nano- and microparticles to tune immunity. Adv Mater (2012) 1.75
The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J Am Chem Soc (2010) 1.63
Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium. Arterioscler Thromb Vasc Biol (2012) 1.55
Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proc Natl Acad Sci U S A (2010) 1.53
Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano (2011) 1.47
Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS Nano (2011) 1.38
Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci U S A (2013) 1.37
On the near-wall accumulation of injectable particles in the microcirculation: smaller is not better. Sci Rep (2013) 1.35
Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. J Control Release (2010) 1.35
Flow dynamics, binding and detachment of spherical carriers targeted to ICAM-1 on endothelial cells. Biorheology (2009) 1.32
PRINT: a novel platform toward shape and size specific nanoparticle theranostics. Acc Chem Res (2011) 1.30
Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. J Control Release (2010) 1.27
Macrophages recognize size and shape of their targets. PLoS One (2010) 1.26
Biomimetic delivery with micro- and nanoparticles. Adv Mater (2012) 1.25
In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. J Control Release (2012) 1.21
Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery. Ther Deliv (2011) 1.17
Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. J Control Release (2010) 1.16
Polymer particles that switch shape in response to a stimulus. Proc Natl Acad Sci U S A (2010) 1.16
Microfluidic devices for modeling cell-cell and particle-cell interactions in the microvasculature. Microvasc Res (2011) 1.15
Polymeric carriers: role of geometry in drug delivery. Expert Opin Drug Deliv (2008) 1.14
The influence of size, shape and vessel geometry on nanoparticle distribution. Microfluid Nanofluidics (2012) 1.13
Multivalent binding of nanocarrier to endothelial cells under shear flow. Biophys J (2011) 1.13
Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond) (2014) 1.07
Challenges in design and characterization of ligand-targeted drug delivery systems. J Control Release (2012) 1.07
Nanocarriers for vascular delivery of antioxidants. Nanomedicine (Lond) (2011) 1.06
Mammalian cells preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake mechanisms. Proc Natl Acad Sci U S A (2013) 1.06
Needle-shaped polymeric particles induce transient disruption of cell membranes. J R Soc Interface (2010) 1.06
Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J Control Release (2008) 1.06
Liquid crystal-based emulsions for synthesis of spherical and non-spherical particles with chemical patches. J Am Chem Soc (2013) 1.05
Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano (2011) 1.03
The shape of things to come: importance of design in nanotechnology for drug delivery. Ther Deliv (2012) 1.03
Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano (2013) 1.02
Acute and chronic shear stress differently regulate endothelial internalization of nanocarriers targeted to platelet-endothelial cell adhesion molecule-1. ACS Nano (2012) 1.02
Dynamic factors controlling targeting nanocarriers to vascular endothelium. Curr Drug Metab (2012) 1.02
New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.01
Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1. J Control Release (2011) 1.01
An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet (2010) 1.00
Self-assembled Tat nanofibers as effective drug carrier and transporter. ACS Nano (2013) 1.00
Dynamic factors controlling carrier anchoring on vascular cells. IUBMB Life (2011) 1.00
Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. Nanomedicine (2011) 0.97
Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1. J Control Release (2012) 0.97
Targeted modulation of reactive oxygen species in the vascular endothelium. J Control Release (2011) 0.97
An inside job: how endosomal Na(+)/H(+) exchangers link to autism and neurological disease. Front Cell Neurosci (2014) 0.96
Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials. Nano Today (2011) 0.96
Nanocarrier Hydrodynamics and Binding in Targeted Drug Delivery: Challenges in Numerical Modeling and Experimental Validation. J Nanotechnol Eng Med (2013) 0.95
Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo. J Control Release (2012) 0.94
Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system. Int J Pharm (2011) 0.94
Margination of micro- and nano-particles in blood flow and its effect on drug delivery. Sci Rep (2014) 0.93
Particle platforms for cancer immunotherapy. Int J Nanomedicine (2013) 0.93
Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor. J Inherit Metab Dis (2012) 0.93
Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano (2013) 0.93
Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano (2014) 0.92
Design of Functional Materials based on Liquid Crystalline Droplets. Chem Mater (2014) 0.90
Silicon micro- and nanofabrication for medicine. Adv Healthc Mater (2013) 0.90
Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders. Drug Deliv Transl Res (2012) 0.89
Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J Control Release (2010) 0.88
Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine (Lond) (2013) 0.88
Liposome-like Nanostructures for Drug Delivery. J Mater Chem B Mater Biol Med (2013) 0.87
Targeting of ICAM-1 on vascular endothelium under static and shear stress conditions using a liposomal Gd-based MRI contrast agent. J Nanobiotechnology (2012) 0.87
Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier. Pharm Res (2014) 0.87
Ellipsoidal Polyaspartamide Polymersomes with Enhanced Cell-Targeting Ability. Adv Funct Mater (2012) 0.86
Icam-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation. PLoS One (2014) 0.86
Filamentous polymer nanocarriers of tunable stiffness that encapsulate the therapeutic enzyme catalase. Biomacromolecules (2009) 0.85
Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles. ACS Nano (2013) 0.85
Neuroprotective and antiinflammatory properties of a novel demethylated curcuminoid. Antioxid Redox Signal (2009) 0.85
Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine (2011) 0.84
In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors. Biomaterials (2013) 0.83
Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice. Int J Nanomedicine (2012) 0.83
Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. Biomaterials (2014) 0.83
USNCTAM perspectives on mechanics in medicine. J R Soc Interface (2014) 0.83
Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting. ACS Nano (2013) 0.82
Shape switching of hollow layer-by-layer hydrogel microcontainers. Chem Commun (Camb) (2011) 0.82
Nanocarriers for vascular delivery of anti-inflammatory agents. Annu Rev Pharmacol Toxicol (2014) 0.81
Emergence and Utility of Nonspherical Particles in Biomedicine. Ind Eng Chem Res (2015) 0.81
Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes. J Control Release (2014) 0.81
Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier. Ther Deliv (2015) 0.81
Shaping the future of nanomedicine: anisotropy in polymeric nanoparticle design. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.80
Characterization of Free and Porous Silicon-Encapsulated Superparamagnetic Iron Oxide Nanoparticles as Platforms for the Development of Theranostic Vaccines. Med Sci (Basel) (2014) 0.80
Size and targeting to PECAM vs ICAM control endothelial delivery, internalization and protective effect of multimolecular SOD conjugates. J Control Release (2016) 0.80
Biomaterial Strategies for Immunomodulation. Annu Rev Biomed Eng (2015) 0.79
Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small (2015) 0.79
Internalization of red blood cell-mimicking hydrogel capsules with pH-triggered shape responses. ACS Nano (2014) 0.79
Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement. Mol Pharm (2014) 0.79
Role of nanoparticle size, shape and surface chemistry in oral drug delivery. J Control Release (2016) 0.79
Dynamics of receptor-mediated nanoparticle internalization into endothelial cells. PLoS One (2015) 0.79
A fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and mice. J Pharmacol Exp Ther (2011) 0.78
In situ re-endothelialization via multifunctional nanoscaffolds. ACS Nano (2014) 0.78
Nanotechnology in interventional cardiology. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.78
Non-affinity factors modulating vascular targeting of nano- and microcarriers. Adv Drug Deliv Rev (2015) 0.78
Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.78
Targeted therapeutics and nanodevices for vascular drug delivery: quo vadis? IUBMB Life (2011) 0.78
Deformable Discoidal Polymeric Nanoconstructs for the Precise Delivery of Therapeutic and Imaging Agents. Mol Ther (2017) 0.78
Targeted endothelial nanomedicine for common acute pathological conditions. J Control Release (2015) 0.77
Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers. Pharm Res (2014) 0.77
Effects of the Microparticle Shape on Cellular Uptake. Mol Pharm (2016) 0.77
Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell (1987) 9.41
Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev (2003) 7.08
Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J (2004) 6.90
Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol (2007) 6.85
Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A (2006) 6.62
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (2004) 3.24
Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation (1998) 2.57
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci (2003) 2.34
PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release (2002) 2.26
Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol (2003) 2.22
Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther (2006) 1.93
Size of IgG-opsonized particles determines macrophage response during internalization. Exp Cell Res (1998) 1.91
Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol (2005) 1.81
Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opin Drug Deliv (2005) 1.61
ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood (2004) 1.58
Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol (2003) 1.54
Advanced drug delivery systems that target the vascular endothelium. Mol Interv (2006) 1.54
Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol (2003) 1.46
Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A (2002) 1.43
Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. Biochim Biophys Acta (1999) 1.30
Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther (2005) 1.29
Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmacol Exp Ther (2008) 1.28
ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood (2003) 1.28
Endothelial endocytic pathways: gates for vascular drug delivery. Curr Vasc Pharmacol (2004) 1.25
Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett (1995) 1.16
Liposome-encapsulated actin-hemoglobin (LEAcHb) artificial blood substitutes. Biomaterials (2005) 1.08
Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther (2002) 1.07
Immunotargeting of catalase to lung endothelium via anti-angiotensin-converting enzyme antibodies attenuates ischemia-reperfusion injury of the lung in vivo. Am J Physiol Lung Cell Mol Physiol (2007) 1.04
Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules. FASEB J (2005) 1.00
17beta-estradiol increases volume, apical surface and elasticity of human endothelium mediated by Na+/H+ exchange. Cardiovasc Res (2006) 0.96
Endocytosis pathways in endothelium: how many? Am J Physiol Lung Cell Mol Physiol (2006) 0.95
Tissue reaction of bioabsorbable ultra high strength poly (L-lactide) rod. A long-term study in rabbits. Clin Orthop Relat Res (1995) 0.94
Early detection of oleic acid-induced lung injury in rats using (111)In-labeled anti-rat intercellular adhesion molecule-1. J Nucl Med (2001) 0.92
Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Mol Ther (2005) 0.92
Tumor vasculature directed drug targeting: applying new technologies and knowledge to the development of clinically relevant therapies. Pharm Res (2002) 0.90
Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium. J Control Release (2007) 0.87
Targeted delivery of therapeutic oligonucleotides to pulmonary circulation. Adv Genet (2005) 0.83
Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A (2006) 6.62
A reversibly switching surface. Science (2003) 3.97
Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med (2008) 3.86
Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov (2004) 3.41
Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release (2007) 2.74
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Cell-selective metabolic labeling of proteins. Nat Chem Biol (2009) 2.61
Discovery of transdermal penetration enhancers by high-throughput screening. Nat Biotechnol (2004) 2.42
Lack of p21 expression links cell cycle control and appendage regeneration in mice. Proc Natl Acad Sci U S A (2010) 2.41
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci (2003) 2.34
Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov (2011) 2.32
Role of particle size in phagocytosis of polymeric microspheres. Pharm Res (2008) 2.23
Oxygen microscopy by two-photon-excited phosphorescence. Chemphyschem (2008) 2.17
The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol (2007) 2.13
Polymer particle shape independently influences binding and internalization by macrophages. J Control Release (2010) 2.05
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol (2003) 2.03
Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther (2006) 1.93
Shape induced inhibition of phagocytosis of polymer particles. Pharm Res (2008) 1.91
Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging (2008) 1.89
Making polymeric micro- and nanoparticles of complex shapes. Proc Natl Acad Sci U S A (2007) 1.84
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
Micro-scale devices for transdermal drug delivery. Int J Pharm (2008) 1.81
Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol (2005) 1.81
Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J (2009) 1.78
PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol (2003) 1.74
The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet (2002) 1.74
The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J (2008) 1.73
Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet (2002) 1.72
Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol (2007) 1.67
Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci U S A (2013) 1.63
ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood (2004) 1.58
Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium. Arterioscler Thromb Vasc Biol (2012) 1.55
Advanced drug delivery systems that target the vascular endothelium. Mol Interv (2006) 1.54
Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol (2003) 1.54
Dynamic control of needle-free jet injection. J Control Release (2009) 1.54
Design principles of chemical penetration enhancers for transdermal drug delivery. Proc Natl Acad Sci U S A (2005) 1.53
Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proc Natl Acad Sci U S A (2010) 1.53
Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res (2005) 1.51
Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer's disease mice by modulation of immune responses. Stem Cells (2010) 1.50
Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol (2003) 1.46
Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des (2010) 1.45
An experimental and theoretical analysis of ultrasound-induced permeabilization of cell membranes. Biophys J (2003) 1.44
Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J Clin Invest (2002) 1.43
Low-frequency sonophoresis: current status and future prospects. Adv Drug Deliv Rev (2008) 1.42
AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol Ther (2005) 1.41
Acid ceramidase and human disease. Biochim Biophys Acta (2006) 1.40
Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci U S A (2009) 1.38
Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci U S A (2013) 1.37
Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A (2009) 1.37
Characterization of common SMPD1 mutations causing types A and B Niemann-Pick disease and generation of mutation-specific mouse models. Mol Genet Metab (2008) 1.37
MoS₂ field-effect transistor for next-generation label-free biosensors. ACS Nano (2014) 1.36
Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. J Control Release (2010) 1.35
Bone marrow-derived mesenchymal stem cells promote neuronal networks with functional synaptic transmission after transplantation into mice with neurodegeneration. Stem Cells (2007) 1.30
Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood (2002) 1.30
In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium. J Nucl Med (2007) 1.30
Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther (2005) 1.29
Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmacol Exp Ther (2008) 1.28
ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood (2003) 1.28
Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. J Control Release (2010) 1.27
Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc Natl Acad Sci U S A (2007) 1.27
Macrophages recognize size and shape of their targets. PLoS One (2010) 1.26
Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol (2008) 1.26
The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics (2004) 1.25
Relationships between skin's electrical impedance and permeability in the presence of chemical enhancers. J Control Release (2005) 1.25
Multifunctional nanoparticles for drug delivery and molecular imaging. Annu Rev Biomed Eng (2013) 1.25
The scarless heart and the MRL mouse. Philos Trans R Soc Lond B Biol Sci (2004) 1.24
Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase. J Biol Chem (2003) 1.24
A fluorescence-based, high-performance liquid chromatographic assay to determine acid sphingomyelinase activity and diagnose types A and B Niemann-Pick disease. Anal Biochem (2003) 1.23
Lipid abnormalities in children with types A and B Niemann Pick disease. J Pediatr (2004) 1.22
Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc Natl Acad Sci U S A (2011) 1.22
Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics (2002) 1.22
Ultrasound-induced cavitation: applications in drug and gene delivery. Expert Opin Drug Deliv (2006) 1.22
Low-frequency sonophoresis: ultrastructural basis for stratum corneum permeability assessed using quantum dots. J Invest Dermatol (2006) 1.21
Investigations of the role of cavitation in low-frequency sonophoresis using acoustic spectroscopy. J Pharm Sci (2002) 1.18
Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials (2007) 1.17
Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. J Control Release (2010) 1.16
Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther (2004) 1.16
Polymer particles that switch shape in response to a stimulus. Proc Natl Acad Sci U S A (2010) 1.16
Antioxidant strategies in respiratory medicine. Treat Respir Med (2006) 1.15
A fluorescence-based, high-throughput sphingomyelin assay for the analysis of Niemann-Pick disease and other disorders of sphingomyelin metabolism. Anal Biochem (2002) 1.14
Improvement in lipid and protein trafficking in Niemann-Pick C1 cells by correction of a secondary enzyme defect. Traffic (2010) 1.14
Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc Natl Acad Sci U S A (2005) 1.14
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood (2010) 1.14
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood (2007) 1.14
Polymeric carriers: role of geometry in drug delivery. Expert Opin Drug Deliv (2008) 1.14
Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim Biophys Acta (2009) 1.13
Acid ceramidase is a novel factor required for early embryo survival. FASEB J (2007) 1.13
Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp Neurol (2008) 1.13
Interactions of inertial cavitation bubbles with stratum corneum lipid bilayers during low-frequency sonophoresis. Biophys J (2003) 1.12
Imprinting at the SMPD1 locus: implications for acid sphingomyelinase-deficient Niemann-Pick disease. Am J Hum Genet (2006) 1.12
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood (2006) 1.11
Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharmacol Exp Ther (2009) 1.11
PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J (2010) 1.11